Last Updated : April 27, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name Sort ascending | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Daxas | Roflumilast | Chronic obstructive pulmonary disease | Do not list | Complete | ||
| Daurismo | Glasdegib | Acute Myeloid Leukemia (AML) | Do not reimburse | Complete | ||
| Darzalex | Daratumumab | BMP for Multiple Myeloma (newly diagnosed) | Reimburse with clinical criteria and/or conditions | Complete | ||
| Darzalex | daratumumab | Multiple myeloma, eligible for autologous stem cell transplant | CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer | Not filed | ||
| Darzalex | Daratumumab | Rd for MM | Reimburse with clinical criteria and/or conditions | Complete | ||
| Darzalex | daratumumab | Light chain (AL) amyloidosis | Reimburse with clinical criteria and/or conditions | Complete | ||
| Darzalex | Daratumumab | Multiple Myeloma (second-line) | Reimburse with clinical criteria and/or conditions | Complete | ||
| Darzalex | Daratumumab | Multiple Myeloma | Do not reimburse | Complete | ||
| Daklinza | Daclatasvir | Hepatitis C, Chronic | List with clinical criteria and/or conditions | Complete | ||
| Daklinza | daclatasvir | Hepatitis C, Chronic | Reimburse with clinical criteria and/or conditions | Complete |
Last Updated : April 27, 2024